Fatal interstitial pneumonitis associated with sirolimus therapy in a heart transplant recipient.
Interstitial pneumonitis is a temporary side effect of sirolimus therapy and has been described mainly in renal transplant recipients. It is considered to be dose dependent and has been documented in patients receiving at least 5 mg daily, or in patients with blood concentration plateaus > 15 ng/ml. In general, clinical and radiologic features improve after discontinuation and, to the best of our knowledge, no reports of fatalities have been published. Our report documents the death in a heart transplant recipient (52-year-old man) that resulted from a loading-dose administration (15 mg), and we report the association of persistently increased blood concentrations (>20 ng/ml) during most of the scheduled administration period.
Manito
Nicolas
N
Heart Transplant Unit, Bellvitge University Hospital, Barcelona, Spain. nml@csub.scs.es
Kaplinsky
Edgardo J
EJ
Bernat
Roger
R
Roca
Josep
J
Castells
Eduardo
E
Serrano
Teresa
T
Esplugas
Enrique
E
D004305:Dose-Response Relationship, Drug; D017809:Fatal Outcome; D016027:Heart Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects*
D007166:Immunosuppressive Agents; D020123:Sirolimus